See more : Green Bridge Industries, Inc. (GRBG) Income Statement Analysis – Financial Results
Complete financial analysis of Ercros, S.A. (ECR.MC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ercros, S.A., a leading company in the Chemicals industry within the Basic Materials sector.
- GME Resources Limited (GME.AX) Income Statement Analysis – Financial Results
- Colowide Co.,Ltd. (7616.T) Income Statement Analysis – Financial Results
- Ximen Mining Corp. (XXMMF) Income Statement Analysis – Financial Results
- Koal Software Co., Ltd. (603232.SS) Income Statement Analysis – Financial Results
- Northcliff Resources Ltd. (NCFFF) Income Statement Analysis – Financial Results
Ercros, S.A. (ECR.MC)
About Ercros, S.A.
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing chipboards, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; plugs and switches in the electrical components sector; and household, sanitary, and packaging materials in the textile tanning industry. The Pharmacy division engages in the production of raw materials and intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, calcium and sodium fosfomycin, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 725.29M | 998.53M | 800.06M | 568.80M | 669.78M | 671.94M | 685.97M | 602.54M | 618.27M | 603.67M | 624.97M | 677.53M | 686.04M | 609.28M | 612.54M | 866.49M | 870.09M | 774.41M | 432.80M | 213.92M | 0.00 |
Cost of Revenue | 519.15M | 692.60M | 532.85M | 348.34M | 439.30M | 435.13M | 433.13M | 359.40M | 298.65M | 311.53M | 329.21M | 356.68M | 367.13M | 309.51M | 294.22M | 496.50M | 842.23M | 424.51M | 246.16M | 0.00 | 0.00 |
Gross Profit | 206.15M | 305.94M | 267.21M | 220.46M | 230.48M | 236.81M | 252.84M | 243.14M | 319.62M | 292.14M | 295.76M | 320.85M | 318.91M | 299.77M | 318.32M | 369.99M | 27.86M | 349.90M | 186.64M | 213.92M | 0.00 |
Gross Profit Ratio | 28.42% | 30.64% | 33.40% | 38.76% | 34.41% | 35.24% | 36.86% | 40.35% | 51.70% | 48.39% | 47.32% | 47.36% | 46.49% | 49.20% | 51.97% | 42.70% | 3.20% | 45.18% | 43.12% | 100.00% | 0.00% |
Research & Development | 472.00K | 271.00K | 305.00K | 418.00K | 403.00K | 464.00K | 425.00K | 180.00K | 220.00K | 440.00K | 310.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 9.55M | 11.62M | 9.60M | 7.18M | 6.67M | 7.10M | 7.34M | 6.91M | 7.36M | 6.74M | 6.44M | 7.48M | 0.00 | 0.00 | 0.00 | 109.14M | 0.00 | 0.00 | 93.50M | 44.77M | 45.31M |
Selling & Marketing | 547.00K | 52.43M | 44.25M | 34.93M | 35.61M | 32.21M | 35.35M | 35.23M | 38.00M | 39.47M | 39.17M | 44.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 10.09M | 64.05M | 53.85M | 42.11M | 42.28M | 39.31M | 42.68M | 42.14M | 45.36M | 46.21M | 45.61M | 52.30M | 0.00 | 0.00 | 0.00 | 109.14M | 0.00 | 0.00 | 93.50M | 44.77M | 45.31M |
Other Expenses | 188.94M | 149.32M | 155.92M | 158.66M | 156.62M | 4.78M | 6.94M | 1.66M | 3.55M | 2.19M | 6.90M | 9.67M | 310.12M | 308.40M | 364.95M | 256.99M | 14.58M | 334.07M | 34.27M | 188.54M | -59.25M |
Operating Expenses | 199.50M | 213.64M | 210.08M | 201.18M | 199.30M | 193.60M | 204.62M | 201.87M | 302.77M | 291.96M | 286.12M | 319.24M | 310.12M | 308.40M | 364.95M | 366.13M | 14.58M | 334.07M | 127.77M | 233.31M | -13.94M |
Cost & Expenses | 694.18M | 906.24M | 742.92M | 549.53M | 638.60M | 628.73M | 637.75M | 561.27M | 601.42M | 603.49M | 615.33M | 675.92M | 677.25M | 617.91M | 659.17M | 862.63M | 856.81M | 758.58M | 373.93M | 233.31M | -13.94M |
Interest Income | 1.03M | 84.00K | 21.00K | 381.00K | 30.00K | 142.00K | 32.00K | 10.00K | 20.00K | 140.00K | 210.00K | 300.00K | 340.00K | 500.00K | 2.84M | 3.23M | 23.75M | 2.10M | 830.00K | 1.40M | 5.42M |
Interest Expense | 9.79M | 3.79M | 3.79M | 4.80M | 5.54M | 4.78M | 5.49M | 5.78M | 6.45M | 8.29M | 9.56M | 10.43M | 11.43M | 5.92M | 5.17M | 10.41M | 7.11M | 15.44M | 21.80M | 830.00K | 4.92M |
Depreciation & Amortization | 35.79M | 44.23M | 34.55M | 33.86M | 33.24M | 30.69M | 28.98M | 23.54M | 19.87M | 18.89M | 19.31M | 18.19M | 18.01M | 19.30M | 16.85M | 39.73M | 40.89M | 40.48M | 27.59M | 13.54M | 13.29M |
EBITDA | 49.04M | 137.84M | 98.80M | 46.85M | 62.61M | 74.35M | 63.38M | 74.72M | 34.76M | 17.27M | 33.39M | 14.36M | 21.84M | 11.29M | -29.78M | -153.54M | 11.08M | 56.31M | 81.17M | -13.58M | 500.00K |
EBITDA Ratio | 6.76% | 12.22% | 10.74% | 8.18% | 9.03% | 9.40% | 9.68% | 10.10% | 6.01% | 3.29% | 4.54% | 2.83% | 4.14% | 1.75% | -4.55% | -17.57% | 9.25% | 7.53% | 20.37% | -8.49% | 0.00% |
Operating Income | 13.04M | 92.16M | 53.68M | 14.94M | 28.71M | 43.21M | 34.33M | 50.87M | 16.85M | 180.00K | 9.14M | -2.88M | 8.79M | -8.63M | -46.63M | 3.86M | -13.03M | 15.83M | 58.87M | -12.92M | -17.97M |
Operating Income Ratio | 1.80% | 9.23% | 6.71% | 2.63% | 4.29% | 6.43% | 5.00% | 8.44% | 2.73% | 0.03% | 1.46% | -0.43% | 1.28% | -1.42% | -7.61% | 0.45% | -1.50% | 2.04% | 13.60% | -6.04% | 0.00% |
Total Other Income/Expenses | -8.01M | -4.20M | -2.53M | -7.95M | -6.09M | -7.03M | -3.32M | -5.73M | -10.10M | -12.69M | -10.14M | -11.06M | -9.85M | -5.19M | -3.25M | -6.68M | -20.27M | -13.42M | -20.12M | -5.37M | 260.00K |
Income Before Tax | 5.03M | 87.96M | 51.16M | 6.99M | 22.63M | 38.00M | 28.68M | 45.31M | 6.75M | -12.51M | -1.00M | -13.94M | -1.06M | -13.82M | -49.88M | -202.38M | -33.30M | 2.41M | 38.75M | -32.95M | -17.71M |
Income Before Tax Ratio | 0.69% | 8.81% | 6.39% | 1.23% | 3.38% | 5.66% | 4.18% | 7.52% | 1.09% | -2.07% | -0.16% | -2.06% | -0.15% | -2.27% | -8.14% | -23.36% | -3.83% | 0.31% | 8.95% | -15.40% | 0.00% |
Income Tax Expense | -23.76M | 17.31M | 7.86M | 728.00K | -8.42M | -6.88M | -15.90M | 150.00K | -490.00K | -5.41M | -680.00K | -940.00K | -160.00K | 60.00K | 1.11M | 203.02M | 210.00K | -2.44M | 250.00K | 70.00K | 50.00K |
Net Income | 27.59M | 62.99M | 43.30M | 6.26M | 31.04M | 44.88M | 44.58M | 45.16M | 7.24M | -6.29M | -3.75M | -12.13M | -900.00K | -12.47M | -49.82M | -20.30B | -33.51M | 4.85M | 38.50M | -32.75M | -17.79M |
Net Income Ratio | 3.80% | 6.31% | 5.41% | 1.10% | 4.63% | 6.68% | 6.50% | 7.49% | 1.17% | -1.04% | -0.60% | -1.79% | -0.13% | -2.05% | -8.13% | -2,343.02% | -3.85% | 0.63% | 8.90% | -15.31% | 0.00% |
EPS | 0.29 | 0.67 | 0.44 | 0.06 | 0.29 | 0.41 | 0.40 | 0.40 | 0.06 | -0.06 | -0.04 | -0.12 | -0.01 | -0.12 | -0.50 | -20.18 | -0.38 | 0.07 | 0.82 | -1.40 | -0.76 |
EPS Diluted | 0.29 | 0.67 | 0.44 | 0.06 | 0.29 | 0.41 | 0.40 | 0.40 | 0.06 | -0.06 | -0.04 | -0.12 | -0.01 | -0.12 | -0.50 | -20.18 | -0.38 | 0.07 | 0.82 | -1.40 | -0.76 |
Weighted Avg Shares Out | 93.59M | 94.23M | 98.78M | 102.62M | 106.15M | 109.17M | 112.27M | 114.09M | 113.99M | 110.18M | 103.52M | 100.77M | 100.62M | 100.65M | 100.62M | 1.01B | 87.15M | 71.87M | 58.48M | 23.39M | 23.39M |
Weighted Avg Shares Out (Dil) | 93.59M | 94.23M | 98.78M | 102.62M | 106.15M | 109.17M | 112.27M | 114.09M | 113.99M | 110.18M | 103.52M | 100.77M | 100.62M | 100.65M | 100.62M | 1.01B | 87.15M | 71.87M | 58.48M | 23.39M | 23.39M |
Source: https://incomestatements.info
Category: Stock Reports